Exploring therapeutic targets in pulmonary sarcomatoid carcinoma by comprehensive genomic profiling.

8073 Background: Pulmonary sarcomatoid carcinoma (SC) is a rare and highly aggressive lung tumor, and it is associated with poor prognosis and high rate of resistance to conventional chemotherapy. The molecular basis of the unique dual differentiation pattern is poorly defined. New therapeutic strategies based on better knowledge of the molecular pathogenesis for pulmonary SC are needed. We used SNP array and high-throughput sequencing technology to identify novel therapeutic molecular targets. Methods: Ten pairs of genomic DNA samples were extracted from fresh frozen tumor tissues and paired normal tissues of patients with pulmonary SC. Whole-exome sequencing at a median of 120× coverage for tumor samples and 60× coverage for normal samples was performed at the Columbia Genome Center. Validation by Illumina TruSeq panel was performed on DNA from formalin-fixed paraffin-embedded (FFPE) tissue from these tumors. In addition, ten of the top ranked genes were chosen for validation by Sanger sequencing on DNA...